Dosing & Uses
Dosage Forms & Strengths
cream
- 0.025%
- 0.01%
ointment
- 0.025%
topical solution
- 0.01%
topical oil
- 0.01%
Shampoo
- 0.01%
Atopic Dermatitis
Body oil: Apply thin film to affected area q8hr
Corticosteroid responsive dermatoses
Cream, ointment, solution: Apply to affected area as a thin film from two to four times daily depending on severity of condition
In hairy sites, the hair should be parted to allow direct contact with lesion
Occlusive dressing may be used for management of psoriasis or recalcitrant conditions
Dosing considerations
- Some plastic films may be flammable; exercise due care in their use; employ caution when such films are used on children or left in their proximity, to avoid possibility of accidental suffocation
- If an infection develops, the use of occlusive dressings should be discontinued, and appropriate antimicrobial therapy instituted
Scalp psoriasis
Scalp oil: Apply thin film onto scalp; massage thoroughly into wet or dampened hair/scalp; cover with shower cap; leave on overnight or for at least 4 hr; wash with shampoo and rinsing thoroughly to remove
Seborrheic dermatitis of the scalp
Shampoo: Apply 1-ounce maximum to scalp once daily; work into a lather and allow to remain on scalp for 5 min; rinse thoroughly with water to remove from hair
Dosing considerations
Patients using topical corticosteroids should receive the following information and instructions
This medication is to be used as directed by physician; it is for external use only; avoid contact with eyes
Patients should be advised not to use medication for any disorder other than that for which it was prescribed
The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician
Patients should report any signs of local adverse reactions, especially under occlusive dressing
Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings
Dosage Forms & Strengths
cream
- 0.025%
- 0.1%
ointment
- 0.025%
topical solution
- 0.01%
topical oil
- 0.01%
Corticosteroid responsive dermatoses
Children and adolescents
- Cream, ointment, solution: Apply to affected area as a thin film from 2-3 times daily depending on severity of condition
- In hairy sites, the hair should be parted to allow direct contact with lesion
- Occlusive dressing may be used for management of psoriasis or recalcitrant conditions
Dosing considerations
- Some plastic films may be flammable; exercise due care in their use; employ caution when such films are used on children or left in their proximity, to avoid possibility of accidental suffocation
- If an infection develops, the use of occlusive dressings should be discontinued, and appropriate antimicrobial therapy instituted
Atopic Dermatitis
Topical oil (0.01%)
≥3 Months and adolescents: Moisten skin with Derma-Smoothe/FS Body oil; apply thin film to affected area BID; not for use >4 weeks
>2 Years and adolescents: Apply thin film of Derma-Smoothe/FS scalp oil to affected area twice daily; not for use >4 weeks
Dosing considerations
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalmic-pituitary-adrenal (HPA) axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio
HPA axis suppression, Cushing’s syndrome, and intracranial hypertension reported in children receiving topical corticosteroids
Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema
Adverse Effects
Frequency Not Defined
Skin atrophy
Striae
Intracranial hypertension
Telangiectasia
Acneiform eruptions
Ketatosis pilaris
Papules
Pustules
Burning
Dryness
Erythema
Pigmentation changes
HPA suppression (with higher potency used >2 wk)
Warnings
Contraindications
Hypersensitivity
Cautions
Chronic topical corticosteroid therapy may interfere with growth & development in pediatric patients
Use med to very high potency for <2 wk to reduce local and systemic side effects
Use low potency for chronic therapy
Kaposi's sarcoma reported with prolonged corticosteroid therapy; if noted, consider discontinuing therapy
Avoid medium to very high potency on face, folds, groin because can increase steroid absorption
Use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted
Contact dermatitis may occur; may be diagnosed as failure to heal rather than clinical exacerbation
As with any topical corticosteroid product, prolonged use may produce atrophy of skin and subcutaneous tissues; when used on intertriginous or flexor areas, or on face, this may occur even with short-term use
In presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted; if a favorable response does not occur promptly, the corticosteroid should be discontinued until infection has been adequately controlled
Avoid contact with the eyes
Patients should be advised not to use this medication for any disorder other than that for which it was prescribed
Shampoo only proven effective in corticosteroid-responsive dermatoses, other than seborrheic dermatitis of the scalp
HPA axis suppression
- Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients
- Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings
- Patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests
- If HPA axis suppression is noted, an attempt should be made to withdraw drug, reduce frequency of application, or substitute a less potent steroid
- Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug
- Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids
- Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation
Pharmacokinetics
Excretion: Urine (primarily); feces (minimal)
Distribution: Throughout local skin
Absorption: Minimal (~1%); nature of skin at application; occlusion and inflammation may increase absorption
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Synalar topical - | 0.01 % solution | ![]() | |
Synalar topical - | 0.01 % solution | ![]() | |
Synalar topical - | 0.025 % cream | ![]() | |
Synalar topical - | 0.025 % ointment | ![]() | |
Derma-Smoothe/FS Body Oil topical - | 0.01 % oil | ![]() | |
fluocinolone topical - | 0.025 % ointment | ![]() | |
fluocinolone topical - | 0.01 % oil | ![]() | |
fluocinolone topical - | 0.025 % ointment | ![]() | |
fluocinolone topical - | 0.01 % oil | ![]() | |
fluocinolone topical - | 0.01 % solution | ![]() | |
fluocinolone topical - | 0.01 % solution | ![]() | |
fluocinolone topical - | 0.025 % cream | ![]() | |
fluocinolone topical - | 0.025 % cream | ![]() | |
fluocinolone topical - | 0.025 % ointment | ![]() | |
fluocinolone topical - | 0.025 % ointment | ![]() | |
fluocinolone topical - | 0.01 % solution | ![]() | |
fluocinolone topical - | 0.025 % ointment | ![]() | |
fluocinolone topical - | 0.01 % cream | ![]() | |
fluocinolone topical - | 0.01 % cream | ![]() | |
fluocinolone topical - | 0.01 % cream | ![]() | |
fluocinolone topical - | 0.01 % solution | ![]() | |
fluocinolone topical - | 0.01 % oil | ![]() | |
fluocinolone topical - | 0.01 % oil | ![]() | |
fluocinolone topical - | 0.01 % cream | ![]() | |
fluocinolone topical - | 0.01 % solution | ![]() | |
fluocinolone topical - | 0.01 % oil | ![]() | |
fluocinolone topical - | 0.01 % solution | ![]() | |
fluocinolone topical - | 0.025 % cream | ![]() | |
fluocinolone topical - | 0.025 % cream | ![]() | |
fluocinolone topical - | 0.025 % ointment | ![]() | |
Capex topical - | 0.01 % shampoo | ![]() | |
Yutiq intravitreal - | 0.18 mg implant | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
fluocinolone intravitreal
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.